Sierra Bancorp announces a new share repurchase program for up to 1 million shares and declares its 107th consecutive quarterly cash dividend of $0.25 per share.
Pulse Biosciences enrolls first patient in NANOCLAMP AF trial using nPulse system for atrial fibrillation treatment.
Centerbridge Partners-backed ML Holdco completes acquisition of MeridianLink for $20 per share, taking the company private and delisting it from the NYSE.
Trilogy Metals announces federal right-of-way permits issued for its Ambler Access Project in Alaska, advancing the critical minerals road.
Aprea Therapeutics reports positive early clinical signals for its WEE1 Kinase Inhibitor APR-1051 in a Phase 1 trial.
Corebridge Financial adds Tomohiro Yao, Nippon Life executive, to its board of directors.